Abstracts tagged "Biomarkers"

Abstract Number: 549 • 2015 ACR/ARHP Annual Meeting
Calprotectin (MRP8/MRP14), a Major Leukocyte Protein, Is Highly Associated to Ultrasound Detected Synovitis and Is Responsive to Biologic Treatment
Hilde Berner Hammer¹, Hilde Haugedal Nordal^2,3 and Tore K. Kvien⁴, ¹Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept of Rheumatology, Haukeland Univerity Hospital, Bergen, Norway, ³Department of Clinical Science, University of Bergen, Broegelmann Research Laboratory, Bergen, Norway, ⁴Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: Calprotectin (MRP8/MRP14, S100A8/A9) is a protein abundant in cytosol of granulocytes and monocytes/macrophages and released during cell activation. It reflects clinical disease activity in…
Abstract Number: 946 • 2015 ACR/ARHP Annual Meeting
Novel Tripartite Motif Proteins Linked to Membrane Integrity As Biomarkers of Dermatomyositis and Polymyositis
Kevin McElhanon¹, Jenna Alloush¹, Nicholas A. Young², Zarife Sahenk³, Rohit Aggarwal⁴, Chester V. Oddis⁵, Wael N. Jarjour² and Noah Weisleder¹, ¹Department of Physiology and Cell Biology, Davis Heart and Lung Research Institute, The Ohio State University College of Medicine, Columbus, OH, ²Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ³Neurology, Research Institute at Nationwide Children's Hospital, Columbus, OH, ⁴Department of Medicine / Rheumtology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁵Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: The mechanisms that contribute to the pathogenesis of the idiopathic inflammatory myopathies remains largely unknown. This heterogeneous group of diseases involve autoimmunity toward muscles…
Abstract Number: 1574 • 2015 ACR/ARHP Annual Meeting
Associations of Serum Anti-Malondialdehyde-Acetaldehyde (MAA) Antibodies with Cardiovascular and Respiratory Mortality in Men with Rheumatoid Arthritis
Bryant R. England¹, Geoffrey M. Thiele², Michael J. Duryee³, Lynell Klassen⁴, Jeremy Sokolove⁵, William H. Robinson⁶, Daniel Anderson⁷, Harlan Sayles⁷, Kaleb Michaud⁸, Liron Caplan⁹, Lisa A. Davis⁹, Grant W. Cannon¹⁰, Brian Sauer¹¹, E. Blair Solow¹², Andreas Reimold¹³, Gail S. Kerr¹⁴, Pascale Schwab¹⁵, Joshua F. Baker¹⁶ and Ted R. Mikuls¹⁷, ¹Division of Rheumatology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ²Research Services 151, Omaha VA Medical Center, Omaha, NE, ³Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁴Dept of Internal Medicine, Univ of Nebraska Med Ctr, Omaha, NE, ⁵Division of Immunology and Rheumatology, Stanford University Medical Center, Mountain View, CA, ⁶Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁷University of Nebraska Medical Center, Omaha, NE, ⁸Rheumatology & Immunology, University of Nebraska Medical Center and National Data Base for Rheumatic Diseases, Omaha, NE, ⁹Div of Rheumatology, Univ of CO Denver School of Med, Aurora, CO, ¹⁰Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ¹¹Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ¹²Rheumatology, UT Southwestern Medical Center, Dallas, TX, ¹³Rheumatology, VAMC, University of Texas Southwestern Medical Center, Dallas, TX, ¹⁴VAMC, Georgetown University, Washington, DC, ¹⁵Div Arth & Rheum Dis, Oregon Health & Sci Univ OP09, Portland, OR, ¹⁶Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁷Medicine, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Mortality from cardiovascular (CV) and respiratory causes is increased in rheumatoid arthritis (RA). Predictive serologic biomarkers of these events are lacking. Previously, we have…
Abstract Number: 1916 • 2015 ACR/ARHP Annual Meeting
Validation of Novel Biomarker Candidates for Systemic Sclerosis
Johannes Schulte-Pelkum¹, Petra Budde¹, Hans-Dieter Zucht¹, Daniel Wirtz¹, Peter Schulz-Knappe¹, Oliver Distler², Suzana Jordan³, Nicolas Hunzelmann⁴, Matthias Schneider⁵ and Britta Maurer², ¹Protagen AG, Dortmund, Germany, ²Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ³Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁴Department of Dermatology, University of Cologne, Cologne, Germany, ⁵Rheumatology, Heinrich-Heine-University, Duesseldorf, Germany
Background/Purpose: Systemic sclerosis (SSc) is a systemic autoimmune disease that manifests as progressive fibrosis of the skin and internal organs. SSc is associated with the…
Abstract Number: 2463 • 2015 ACR/ARHP Annual Meeting
Soluble Low-Density Lipoprotein Receptor-Related Protein 1 in Juvenile Idiopathic Arthritis
Alan M. Rosenberg¹, Marianna Newkirk², Elham Rezaei¹, Zhenhong Li³ and Kiem Oen⁴, ¹Pediatrics, University of Saskatchewan, Saskatoon, SK, Canada, ²Medicine, McGill University Health Centr, Montreal, QC, Canada, ³McGill University Health Centr, Montreal, QC, Canada, ⁴University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Low-density lipoprotein receptor–related protein 1 (LRP1), a transmembrane protein, mediates endocytosis of an array of extracellular ligands. LRP1 has intracellular and extracellular domains. With…
Abstract Number: 2834 • 2015 ACR/ARHP Annual Meeting
CXCL10 Expression Is Elevated in Synovial Fluid of Psoriatic Arthritis Patients
Anastasiya Muntyanu¹, Fatima Abji², Kun Liang³, Vinod Chandran⁴ and Dafna Gladman⁴, ¹Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ²Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ³Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ⁴Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA), an inflammatory musculoskeletal disease, develops in approximately 30% of patients with psoriasis. We previously identified C-X-C motif chemokine 10 (CXCL10) as…
Abstract Number: 168 • 2015 ACR/ARHP Annual Meeting
Ultrasound Evaluation of the Efficacy of Biologic and Targeted Synthetic Dmards Toward Rheumatoid Arthritis Patients: Kyushu Multicenter Rheumatoid Arthritis Ultrasound Prospective Observational Cohort in Japan
Ayako Nishino^1,2, Shin-ya Kawashiri^1,2, Atsushi Kawakami^1,2, Tamami Yoshitama², Nobutaka Eiraku², Noki Matsuoka², Yukitaka Ueki², Akitomo Okada², Hiroaki Hamada², Toshihiko Hidaka², Shuji Nagano², Tomomi Tsuru², Keita Fujikawa² and Yojiro Arinobu², ¹Department of Immunology and Rheumatology, Nagasaki University, Nagasaki, Japan, ²Kyushu multicenter rheumatoid arthritis ultrasound prospective observational cohort study group, Nagasaki, Japan
Background/Purpose: Few prospective ultrasound (US) cohort studies of rheumatoid arthritis (RA) patients treated by biologic or targeted synthetic DMARDs (b/tsDMARDs) are reported. We have been…
Abstract Number: 574 • 2015 ACR/ARHP Annual Meeting
Metabolomic Profiling Predicts Outcome of Rituximab Therapy in Rheumatoid Arthritis
Shannon Sweeney¹, Arthur Kavanaugh², Alessia Lodi³, Bo Wang¹, David L. Boyle⁴, Stefano Tiziani⁵ and Monica Guma⁶, ¹University of Texas at Austin, Austin, TX, ²University of California San Diego, La Jolla, CA, ³nutritional Sciences, University of Texas at Austin, Austin, TX, ⁴Division of Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla, CA, ⁵Nutritional Sciences, University of Texas at Austin, Austin, TX, ⁶Pharmacology, University of California, San Diego, La Jolla, CA
Background/Purpose: We hypothesized that characterization of patients’ metabolic profiles, utilizing both high-resolution 1H-nuclear magnetic resonance (NMR) and mass spectrometry (MS), might help predict response to…
Abstract Number: 1021 • 2015 ACR/ARHP Annual Meeting
Nucleic Acids Sensing Receptors RIG-I and MDA5 As Potential Amplifiers of the Interferon Signature in Childhood Onset Systemic Lupus Erythematosus
Naomi I Maria¹, M. Javad Wahadat¹, Cornelia G. van Helden-Meeuwsen¹, Annette van Dijk-Hummelman², Radboud JEM Dolhain³, Sylvia Kamphuis² and Marjan A. Versnel¹, ¹Immunology, Erasmus Medical Center, Rotterdam, Netherlands, ²Pediatric Rheumatology, Eramus MC Sophia Children's Hospital, Rotterdam, Netherlands, ³Rheumatology, Erasmus Medical Center, Rotterdam, Netherlands
Background/Purpose: Defective or sustained activation of Interferon (IFN) signaling has been associated with enhanced susceptibility to systemic lupus erythematosus (SLE). The cytosolic RIG-I-like receptors (RLRs),…
Abstract Number: 1575 • 2015 ACR/ARHP Annual Meeting
Serum Vascular Cell Adhesion Molecule-1 (VCAM-1) Levels Are Associated with Vascular Dysfunction and Increased Cardiovascular Risk in an Animal Model and Patients with Rheumatoid Arthritis
Ruth Davies¹, Daniela Iacono², Lauren A. Jordan¹, Jessica O Williams¹, Charlotte Rawlings¹, Derek Lang³, Anwen S. Williams¹ and Ernest H. Choy¹, ¹Cardiff University, Institute of Infection and Immunity, Tenovus Building, University Hospital of Wales, Cardiff, United Kingdom, ²Department of Clinical and Experimental Medicine. Rheumatology Section. Second University of Naples, Naples, Italy, ³Institute of Molecular and Experimental Medicine, Cardiff University School of Medicine, Cardiff, United Kingdom
Background/Purpose: Mortality is increased in Rheumatoid arthritis (RA) patients mainly due to cardiovascular (CV) disease; however the biologic mechanisms are unknown. Increased CV risk in…
Abstract Number: 1917 • 2015 ACR/ARHP Annual Meeting
Developing and Validating a Serum Biomarker for the Extent of Skin Disease in Patients with Diffuse Cutaneous Systemic Sclerosis
Lisa Rice¹, Julio Mantero², Giuseppina Stifano¹, Jessica Ziemek³, Robyn T. Domsic⁴ and Robert Lafyatis¹, ¹Boston University School of Medicine, Boston, MA, ²Rheumatology, Boston University School of Medicine, Boston, MA, ³Rheumatology/Arthritis Center, Boston University School of Medicine, Boston, MA, ⁴Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: In this study we aimed to both agonistically investigate alterations in the serum proteome of patients with diffuse cutaneous systemic sclerosis (dcSSc), as well…
Abstract Number: 2584 • 2015 ACR/ARHP Annual Meeting
Prediction of Disease Relapses By Multi-Biomarker Disease Test Activity in Rheumatoid Arthritis Patients Tapering DMARD Treatment
Juergen Rech¹, Axel J. Hueber², Matthias Englbrecht², Stephanie Finzel³, Judith Haschka^4,5, Bernhard Manger², Arnd Kleyer³, Michaela Reiser³, Hans-Peter Tony⁶, Stefan Kleinert⁷, Martin Feuchtenberger⁸, Martin Fleck⁹, Karin Manger¹⁰, Wolfgang Ochs¹¹, Matthias Schmitt-Haendle¹², Joerg Wendler¹³, Florian Schuch¹³, Monika Ronneberger¹³, Hanns-Martin Lorenz¹⁴, Hubert Nüßlein¹⁵, Rieke Alten¹⁶, Jayme Fogagnolo Cobra¹⁷, Joerg C. Henes¹⁸, Klaus Krüger¹⁹ and Georg A. Schett²⁰, ¹medical clinic 3, University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Internal Medicine 3, Rheumatology & Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ³Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, ⁴Medical Department 3, Rheumatology & Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁵Medical Department II, Medical University of Vienna, St. Vincent Hospital Vienna,, Vienna, Austria, ⁶University Hospital Würzburg, Würzburg, Germany, ⁷Rheumatologische Schwerpunktpraxis Erlangen, Erlangen, Germany, ⁸Rheumatologie/Klinische Immunologie, Kreiskliniken Altötting-Burghausen, Burghausen, Germany, ⁹Department of Internal Medicine I, University of Regensburg, 93042 Regensburg, Germany, ¹⁰Rheumatology Practice Bamberg, Bamberg, Germany, ¹¹Rheumatologist in Private Practice, Bayreuth, Germany, ¹²Rheumatology Practice, Bayreuth, Germany, ¹³Schwerpunktpraxis Rheumatologie, Erlangen, Germany, ¹⁴University Hospital Heidelberg, Heidelberg, Germany, ¹⁵University Erlangen, Nürnberg, Germany, ¹⁶Internal Medicine, Rheumatology & Clinical Immunology, Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, ¹⁷Instituto de Reumatologia de Sao Paolo, Sao Paolo, Brazil, ¹⁸Department of Internal Medicine II, Rheumatology Division, University Hospital Tuebingen, Tuebingen, Germany, ¹⁹Praxiszentrum St. Bonifatius, München, Germany, ²⁰University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: To analyze the role of multi-biomarker disease activity (MBDA) in predicting disease relapses in rheumatoid arthritis (RA) patients in sustained remission, tapering disease modifying…
Abstract Number: 2965 • 2015 ACR/ARHP Annual Meeting
Might Troponin be a Marker for Subclinical Scleroderma Heart Involvement (SHI)?
Chiara Stagnaro¹, Anna d'Ascanio¹, Alice Parma², Umberto Conti³, Michele Emdin⁴, Alessandra Della Rossa¹ and Marta Mosca¹, ¹Internal Medicine, University of Pisa, Pisa, Italy, ²University of Pisa, Pisa, Italy, ³Cardiotoracico, Cardiologia 2, Pisa, Italy, ⁴Fondazione Toscana Gabriele Monasterio, UOC Cardiologia e Medicina Cardiovascolare, Pisa, Italy
Background/Purpose: Systemic sclerosis (SSc) is a rare connective tissue disease with pronounced alterations of the microvascular system, frequent cellular and humoral immunity abnormalities and fibroblast…
Abstract Number: 2880 • 2014 ACR/ARHP Annual Meeting
Elevated Levels of Soluble Inflammatory Mediators and Lupus-Specific Connective Tissue Disease Questionnaire Scores Discern Unaffected First Degree Relatives of Lupus Patients from Unaffected Individuals Not Related to Lupus Patients
Melissa E. Munroe¹, Kendra A. Young², Jennifer Fessler³, Dustin Fife³, Diane L. Kamen⁴, Joel M. Guthridge³, Timothy B. Niewold⁵, Michael H. Weisman⁶, Mariko L. Ishimori⁶, Daniel J. Wallace⁷, David R. Karp⁸, John B. Harley⁹, Gary S. Gilkeson⁴, Jill M. Norris² and Judith A. James^10,11, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Epidemiology, Colorado School of Public Health, Aurora, CO, ³Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ⁵Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ⁶Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁷Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁸Rheumatic Diseases Division, UT Southwestern Medical Center, Dallas, TX, ⁹Center for Autoimmune Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁰Clinical Arthritis and Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹¹Rheumatology, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Identifying populations at risk of SLE is essential to curtail inflammatory damage and select individuals for prevention trials. First-degree relatives (FDRs) of lupus patients…
Abstract Number: 1897 • 2014 ACR/ARHP Annual Meeting
Circulating T-Helper Cell- Associated Cytokines and Chemokines in Localized Scleroderma
Kathryn S. Torok¹, Katherine Kurzinski², Christina Kelsey³, Kelsey Magee⁴, Jonathan Yabes⁵, Abbe N. Vallejo⁶, Thomas A. Medsger Jr.⁷ and Carol A. Feghali-Bostwick⁸, ¹Pediatric Rheumatology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ²Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, ³Pediatric Rheumatology, University of Pittsburgh/UPMC, Pittsburgh, PA, ⁴Pediatric Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁵Department of Medicine, University of Pittsburgh, Pittsburgh, PA, ⁶Department of Immunology, University of Pittsburgh, Pittsburgh, PA, ⁷Medicine/Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁸Medicine, Medical University of South Carolina, Charleston, SC
Background/Purpose: Localized scleroderma (LS) is an autoimmune disease of the skin and underlying tissues which results in disfigurement and orthopedic complications, especially when the onset…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].